Drug Topics
JULY 14, 2025
Currently it’s going to be slowing to upper single digits through the forecast period, basically because 2 of the leading drugs, there's immune checkpoint inhibitors—nivolumab is the molecule—and pembrolizumab is Keytruda, 2 of those are going off patent in 2028 and 2029. That trend is in the low-to-mid teens in terms of growth rate.
PharmaVoice
JULY 8, 2025
You just want to slash it, rip it out or attack it like an enemy target,” said Benjamin Zeskind, co-founder, CEO and president of Immuneering Corporation. To overcome that hurdle, Immuneering is testing an approach that slows cancer down rather than rushing to destroy it.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 16, 2025
Further, the incidence, severity, and kinetics of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome with CD20 × CD3 TCEs may vary depending on the B-cell lymphoma subtype and the combination partners used, which is a notable consideration for oncology pharmacists when operationalizing these therapies.
The Checkup by Singlecare
AUGUST 7, 2025
Offer special considerations for high-risk patients People with weakened immune systems due to health conditions or immune-suppressing medications are more likely to get sick from food poisoning, according to the CDC. Pregnant women should also avoid high-risk foods. Offer OTC remedies Mild food poisoning is often self-limited.
Pharmacy Times
JUNE 9, 2025
SHOW MORE Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option. The CheckMate 816 trial showed a high pathological complete response rate without increased adverse events, supporting nivolumab as a standard treatment.
Pharmacy Times
JUNE 27, 2025
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.
Pharmacy Times
JUNE 18, 2025
Wick, MBA, RPh, FASCP Key Takeaways Pharmacists can address SDOH by providing patient-centered care, promoting immunizations, and offering point-of-care testing to improve health outcomes. Offering and promoting immunizations and point-of-care testing are 2 proven ways to address SDOH.
Expert insights. Personalized for you.
Let's personalize your content